FINHUB Insights

Pfizer Q2 FY25: where the revenue came from and where it went

The whole income statement of Pfizer for this quarter, as one diagram: what earned the revenue, and what it went on.

Period
Mar 31 – Jun 29, 2025
Reported
Aug 5, 2025 10-Q accession 0000078003-25-000138

Revenue$14.7B +10% year over year
Gross profit$10.9B 74% margin
Operating profit−$3.1B −21% margin
Net profit$2.9B 20% margin

Net profit is larger than what operations earned, because the statement adds $6.1B below it, under Other income, net.

100% free

It's free. All of it.

A free account opens every diagram. We send one link to confirm your address, and that is the whole of it.

Already have an account? Sign in

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 29, 2025).
ItemValueShare of revenueYear over year
Revenue 14.7 100% +10%
US 8.9 61% +13%
Developed markets 3.4 23% +7%
International emerging 2.4 16% +6%
Cost of revenue−3.826%
Gross profit10.974% margin−1pp
SG&A−3.423%−5pp
Other−10.572%+0pp
Operating profit−3.1−21% margin+0pp
Other income, net6.1
Tax−0.1
Net profit2.9 20% margin+20pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

359 of 418 companies, most recently reported first